Inlabs Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 28-10-2024
- Paid Up Capital ₹ 0.11 M
as on 28-10-2024
- Company Age 2 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit -6644.63%
(FY 2023)
- Ebitda -9032.57%
(FY 2023)
- Net Worth 723.12%
(FY 2023)
- Total Assets 4484.99%
(FY 2023)
About Inlabs Lifesciences
The Company is engaged in the Fmcg Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.11 M, as per Ministry of Corporate Affairs (MCA) records.
Vidhu Jain and Kanika serve as directors at the Company.
- CIN/LLPIN
U74999DL2022PTC392849
- Company No.
392849
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Jan 2022
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Inlabs Lifesciences Private Limited offer?
Inlabs Lifesciences Private Limited offers a wide range of products and services, including Ayurveda Cosmetics, Vitamin K Cream, Nutritional Supplements, Niacinamide.
Who are the key members and board of directors at Inlabs Lifesciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vidhu Jain  | Director | 25-Jan-2022 | Current |
| Kanika | Director | 25-Jan-2022 | Current |
Financial Performance of Inlabs Lifesciences.
Inlabs Lifesciences Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 6644.63% decrease in profit. The company's net worth Soared by an impressive increase of 723.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Inlabs Lifesciences?
Unlock access to Inlabs Lifesciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Inlabs Lifesciences?
Inlabs Lifesciences has a workforce of 0 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Inlabs Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Inlabs Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
